Mupirocine Eg (Mupirocin)

Mupirocin blocks the bacterial enzyme isoleucyl‑tRNA synthetase, which is required for attaching the amino acid isoleucine to its tRNA during protein synthesis. By inhibiting this step, the drug stops bacterial cells from producing essential proteins, leading to a bacteriostatic effect at low concentrations and a bactericidal effect at higher concentrations against susceptible organisms.

The dosage of Mupirocine Eg is determined by the prescribing healthcare professional based on the infection type, size, and patient factors. Typically, a thin layer is applied to the affected area one to three times daily, but the exact regimen should follow the prescriber’s instructions.

Safety data for mupirocin in pregnancy and lactation are limited. It is generally advised to use the medication only if the potential benefit justifies any potential risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss use with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, and will request trade or institutional credentials. The sales team then replies with pricing, availability, shipping details (including any cold‑chain requirements), and the necessary import documentation.

Mupirocin offers a narrow spectrum of activity primarily against Gram‑positive organisms, including methicillin‑resistant Staphylococcus aureus (MRSA). Compared with bacitracin or neomycin, mupirocin has a lower risk of allergic contact dermatitis and retains activity against certain resistant strains, making it a preferred choice for impetigo and MRSA‑related skin infections.

Mupirocine Eg should be stored at room temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed when not in use to maintain stability.

The medication is applied topically to clean, dry skin. A thin layer should be spread over the affected area, usually once to three times per day, as directed by a healthcare professional. Hands should be washed before and after application, and the treated area should be covered only if advised.

Serious risks, though rare, include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, toxic epidermal necrolysis, and systemic effects like neutropenia from extensive absorption. Patients should discontinue use and seek immediate medical attention if they experience widespread rash, blistering, fever, or signs of an allergic reaction.

Mupirocine Eg should not be used by individuals with a known hypersensitivity to mupirocin or any component of the formulation. It is also contraindicated on large areas of healthy skin without infection, on mucous membranes, or in patients where systemic antibiotic therapy is more appropriate.